Application of antisense oligonucleotide in preparation of glioma treatment drug

By designing the all-thioantised oligonucleotide S-ASODN-1 targeting IGF1R, the problem of lack of IGF1R target in the prior art to treat gliomas is solved, and significant proliferation inhibition of human glioma cells is achieved. and tumor growth inhibition are significantly better than existing drugs.

CN118987016APending Publication Date: 2024-11-22BEIJING YUEKANGKECHUANG PHARM TECH CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202310553421.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

There are no drugs targeting the insulin-like growth factor-1 receptor IGF1R among the existing glioma treatment drugs, and the currently under development of drug indications targeting the IGF1R receptor do not involve gliomas and lack effectiveness. targeted therapy options.

Method used

S-ASODN-1, a full thioanti-sense oligonucleotide targeting IGF1R, was designed and synthesized, interfering with the IGF1R signaling pathway through base complementary pairing with specific sequences, inhibiting glioma cell proliferation and tumor growth.

Benefits of technology

S-ASODN-1 significantly inhibits the proliferation of human glioma cell lines U87, U251, and SHG-44, has dose-dependent and continuous inhibitory effects, which is better than the existing positive control cisplatin and effectively inhibits glioma tumor growth .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004232119960000011
    Figure BDA0004232119960000011
  • Figure BDA0004232119960000041
    Figure BDA0004232119960000041
  • Figure BDA0004232119960000051
    Figure BDA0004232119960000051
Patent Text Reader

Abstract

The invention relates to application of antisense oligonucleotide in preparation of a medicine for treating glioma, in particular to application of antisense oligonucleotide taking insulin-like growth factor-1 receptor IGF1R gene as a target or a composition of the antisense oligonucleotide in inhibition of glioma cell proliferation and treatment of glioma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of gene therapy for gliomas, and specifically to the use of a fully phosphorothioated antisense oligonucleotide targeting the insulin-like growth factor-1 receptor IGF1R gene or a composition thereof in inhibiting glioma cell proliferation and treating gliomas. Background Art

[0002] Antisense oligonucleotides (ASODNs) are a class of synthetic oligonucleotide fragments, typically 15 to 30 nucleotides in length. They primarily interfere with the transcription and translation of target genes through complementary base pairing, thereby achieving targeted gene therapy. ASODNs are considered highly promising gene therapy drugs due to their abundant candidate targets, rationally designed targets, high efficacy in vitro and in vivo, and amenable to large-scale synthetic synthesis. In recent years, breakthroughs in nucleotide chemical modification and delivery technologies have ushered in a new wave of ASODN drug development. Several renowned pharmaceutical companies, both domestically and internationally, have prioritized antisense drugs as a key area of ​​their new drug development. Currently, nine antisense oligonucleotides are marketed (Table 1).

[0003] Table 1 Marketed antisense oligonucleotide drugs

[0004]

[0005] Gliomas refer to tumors originating from brain glial cells and are the most common primary intracranial tumors. The 2021 edition of the WHO Classification of Tumors of the Central Nervous System divides gliomas into grades 1 to 4, with grades 1 and 2 being low-grade gliomas and grades 3 and 4 being high-grade gliomas.

[0006] The annual incidence of glioma in my country is 5-8 per 100,000 people, and its five-year mortality rate is second only to pancreatic and lung cancers among systemic tumors. The pathogenesis of glioma remains unclear, but two identified risk factors are exposure to high-dose ionizing radiation and high-penetrance genetic mutations associated with rare syndromes. Furthermore, carcinogenic factors such as nitrite-rich foods and viral or bacterial infections may also contribute to the development of glioma.

[0007] The clinical manifestations of gliomas primarily include increased intracranial pressure, neurological and cognitive impairment, and epileptic seizures. Currently, clinical diagnosis relies primarily on imaging modalities such as CT and MRI. Diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI), perfusion-weighted imaging (PWI), magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI), and positron emission tomography (PET) are crucial for the differential diagnosis and treatment evaluation of gliomas. The definitive diagnosis of gliomas requires specimens obtained through surgical resection or biopsy, followed by integrated histopathology and molecular pathology to determine pathological grade and molecular subtype. Molecular markers are crucial for personalized treatment and clinical prognosis of gliomas.

[0008] The treatment of brain glioma is mainly surgical resection, combined with comprehensive treatment methods such as radiotherapy and chemotherapy. Surgery can relieve clinical symptoms, prolong survival, and obtain sufficient tumor specimens for clear pathological diagnosis and molecular genetic testing. The principle of surgical treatment is to safely resect the tumor to the maximum extent, and new technologies such as conventional neuronavigation, functional neuronavigation, intraoperative neuroelectrophysiological monitoring and intraoperative MRI real-time imaging can help achieve the maximum safe resection of the tumor. Radiotherapy can kill or inhibit tumor cells and prolong patient survival. Conventional fractionated external beam irradiation is the standard treatment for brain glioma radiotherapy. Postoperative radiotherapy for glioblastoma (GBM) combined with synchronous temozolomide and adjuvant temozolomide chemotherapy has become the standard treatment for newly diagnosed GBM in adults.

[0009] Glioma treatment requires a multidisciplinary team (MDT), encompassing neurosurgery, neuroimaging, radiotherapy, neuro-oncology, pathology, and neurorehabilitation. Following the principles of evidence-based medicine, individualized comprehensive treatment is adopted, with optimized and standardized treatment plans to maximize therapeutic benefit, prolong progression-free and overall survival, and improve quality of life. To ensure optimal comprehensive treatment, physicians must closely follow up and manage patients throughout the entire process, including regular imaging reviews and consideration of various aspects of the patient's daily life, social and family activities, nutritional support, pain control, rehabilitation, and psychological well-being.

[0010] Therefore, there is a need in the art to develop drugs for treating gliomas. Summary of the Invention

[0011] In this regard, the present invention discloses a method for treating glioma by designing an antisense oligonucleotide S-ASODN-1 with a unique sequence targeting the insulin-like growth factor-1 receptor IGF1R. The results show that the antisense oligonucleotide can treat glioma, thus solving the above-mentioned technical problems.

[0012] The present disclosure discovered for the first time that an antisense oligonucleotide S-ASODN-1 with a specific sequence targeting the insulin-like growth factor-1 receptor IGF1R can effectively inhibit the proliferation of glioma cells and the growth of glioma tumors, and is used to treat gliomas. In fact, none of the existing drugs for treating gliomas that have been approved or have entered the clinical stage target the insulin-like growth factor-1 receptor IGF1R. In addition, the indications of the drugs currently under development that target the IGF1R receptor do not involve gliomas (see Tables 2 and 3 below for specific descriptions). In addition, not all antisense oligonucleotides targeting any sequence of IGF1R can treat gliomas. The results of the cell proliferation inhibition experiment disclosed in the present disclosure show that the inhibitory activity of this series of fully thiolated antisense oligonucleotides on glioma cells varies greatly. For example, S-ASODN-1 has a significant inhibitory effect on activity, which is comparable to the effect of the positive control cisplatin; while other antisense oligonucleotide sequences S-ASODN-2, S-ASODN-3, S-ASODN-4, and S-ASODN-5 are unable to inhibit glioma cell proliferation and glioma tumor growth and cannot be used to treat gliomas (see Example 2).

[0013] Gliomas are the most common primary malignant brain tumors in adults. They can arise anywhere in the central nervous system but primarily develop in the brain and glial tissue. Lack of consistency in glioma definitions, varying histologic types, and differences in data collection techniques can complicate statistical comparisons of incidence rates across different sources. The overall age-adjusted incidence of all gliomas ranges from 4.67 to 5.73 per 100,000 population. Glioblastoma, the most common and lethal glioma subtype in adults, has an age-adjusted incidence of 0.59 to 3.69 per 100,000 population.

[0014] Glioma is characterized by infiltrative growth, with no clear boundary between it and normal brain tissue. Most tumors extend beyond the cerebral lobes, extending into the brain in a finger-like pattern, deeply damaging it. Benign tumors grow slowly and have a long course, with an average time from symptom onset to medical consultation of two years. Malignant tumors grow rapidly and have a shorter course, with most cases progressing from symptom onset to medical consultation within three months, and 70-80% within six months. Glioma incidence also has its own unique characteristics, with rapid proliferation and a long time to resection. A second characteristic is that gliomas can grow quite large. Third, surgery can worsen gliomas.

[0015] Table 2 introduces the drugs that have been approved or entered the clinical stage for the treatment of glioma. As can be seen from Table 2, none of the drugs currently under research for the treatment of glioma targets the insulin-like growth factor-1 receptor IGF1R.

[0016]

[0017]

[0018]

[0019]

[0020]

[0021]

[0022]

[0023]

[0024]

[0025]

[0026]

[0027]

[0028]

[0029]

[0030] Insulin-like growth factors (IGFs), also known as somatomedins, include IGF-I and IGF-II. These growth factors exert their biological effects only when bound to their receptor, IGF1R. The IGF1R, a member of the receptor tyrosine kinase family, is located on the cell membrane. Upon binding to IGFs, it dimerizes, bringing the tyrosine domains into close proximity and triggering autophosphorylation. This subsequently activates intracellular signaling pathways related to cell proliferation, including RAS-RAF-MAPK and PI3K-PKB / AKT. IGF1R activation is crucial for stimulating tumor cell growth and survival.

[0031] Table 3 shows the indications of drugs currently under development that target the IGF1R receptor, none of which involve glioma.

[0032] Table 3 Information on drugs under development targeting IGF1R receptor

[0033]

[0034] Briefly, this disclosure designs anti-tumor antisense oligonucleotides based on the previously published insulin-like growth factor-1 receptor (IGF1R) mRNA sequence BC113610.1. Online blast sequence alignment with GeneBank confirmed that the selected target sequence exhibits excellent specificity and does not interfere with the expression of other normal human genes. Several of the designed antisense oligonucleotides were fully phosphorothioated to prolong their in vivo action and synthesized using a solid-phase method.

[0035] The results of the cell proliferation inhibition experiments disclosed in this paper indicate that not all antisense oligonucleotides targeting IGF1R are capable of treating gliomas. This series of fully phosphorothioated antisense oligonucleotides exhibited significant differences in their inhibitory activity against glioma cells. Among them, S-ASODN-1 exhibited a significant inhibitory effect, significantly outperforming the positive control, cisplatin. In contrast, the other antisense oligonucleotide sequences, S-ASODN-2, S-ASODN-3, S-ASODN-4, and S-ASODN-5, failed to inhibit glioma cell proliferation or tumor growth and are therefore unsuitable for treating gliomas.

[0036] S-ASODN-1 inhibited the proliferation of human glioma cells U87, U251, and SHG-44 to varying degrees within the concentration range of 100 to 1600 nM. Among them, S-ASODN-1 showed the greatest inhibitory effect on the human glioma cell line U87. At a concentration of 1600 nM, the inhibitory rates of S-ASODN-1 on U87, U251, and SHG-44 cells were 65.58%, 62.96%, and 61.16% after 24 hours; 65.83%, 65.31%, and 62.86% after 48 hours; and 67.82%, 66.82%, and 63.67% after 72 hours.

[0037] Furthermore, S-ASODN-1's inhibitory effect on the proliferation of various glioma cells is dose-dependent, with the inhibitory effect gradually increasing with increasing S-ASODN-1 concentration. The inhibitory effect of S-ASODN-1 on various human glioma cell lines is sustained, with the inhibitory activity of S-ASODN-1 gradually increasing over one to three days.

[0038] The results of growth inhibition experiments on human glioma cell lines U87, U251, and SHG-44 transplanted tumor models showed that all S-ASODN-1 administration groups had inhibitory effects on the growth of human glioma cells. Although the inhibitory effect of the low-dose group (3.75 mg / kg) was slightly lower than that of the positive control sorafenib group (20 mg / kg), the inhibitory effects of the medium-dose group (7.5 mg / kg) and the high-dose group (15 mg / kg) were significantly better than those of the positive control sorafenib. Different dose groups can effectively inhibit the growth of glioma tumors and are used to treat gliomas.

[0039] Therefore, targeting the insulin-like growth factor-1 receptor ICF1R is used to treat gliomas.

[0040] Specifically, the present disclosure provides the following technical solutions:

[0041] On the one hand, the present disclosure relates to the use of a therapeutically effective amount of a thiocyanate antisense oligonucleotide targeting the IGF1R gene or a composition thereof in the preparation of a medicament for inhibiting glioma cell proliferation and treating glioma in a subject suffering from glioma, wherein the sequence of the thiocyanate antisense oligonucleotide targeting the IGF1R gene comprises a nucleotide sequence having more than 80% nucleotide identity with the 5'-TCCTCCGGAGCCAGACTTCA-3' sequence, preferably a nucleotide sequence having more than 85%, 90%, 95%, 96%, 97%, 98%, or 99% nucleotide identity; more preferably, the sequence of the thiocyanate antisense oligonucleotide targeting the IGF1R gene is 5'-TCCTCCGGAGCCAGACTTCA-3' (SEQ ID NO: 1).

[0042] The term "nucleotide identity" refers to the percentage of the number of identical nucleotides in two nucleotide sequences to the number of nucleotides in one of the nucleotide sequences. For example, the sequence shown in SEQ ID NO:6 is 5'-TCCTCCGGAGCCAGACTTCA-3' (20 nucleotides), and the sequence shown in SEQ ID NO:7 is TCCTCTCGGAGCCAGACTT (18 nucleotides). The sequence shown in SEQ ID NO:7 has 90% nucleotide identity with the sequence shown in SEQ ID NO:6.

[0043] The term "therapeutically effective amount" or "therapeutically effective dose" refers to an amount of a substance, compound, material, or composition comprising a compound that is at least sufficient to produce a therapeutic effect after administration to a subject. Thus, it is the amount necessary to prevent, cure, ameliorate, arrest, or partially arrest the symptoms of a disease or condition.

[0044] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting the IGF1R gene or a composition thereof disclosed herein, the phosphorothioate antisense oligonucleotide targeting the IGF1R gene further has other chemical modifications.

[0045] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting the IGF1R gene or a composition thereof disclosed herein, the other chemical modifications are selected from one or more of the following: locked nucleic acid modification, 2-methoxyethyl modification, and 2-oxymethyl modification.

[0046] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, the composition further comprises at least one additional active agent.

[0047] In a preferred embodiment, in the use of the therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, the at least one additional active agent is a therapeutic agent or a non-therapeutic agent, or a combination of a therapeutic agent and a non-therapeutic agent.

[0048] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting the IGF1R gene or a composition thereof disclosed herein, wherein the at least one additional active agent is a therapeutic agent selected from one or more of the following: temozolomide, lomustine, bevacizumab, SI-053, Gliovac, Immuncell-LC, ipilimumab, dehydrodulcitol, tofacitinib, regorafenib, nivolumab, cediranib, ADCTA-SSI-G1, AV-GBM-1, DCVax-L, ICT-107, ITK-1, ASC40 (denifanstat), marizomib, ofranergene obadenovec, personalized peptide vaccine, trabedersen, enzastaurin, crocetin, benzylguanine, OncoPLEX, flucytosine, vebreltinib, trigriluzole, veliparib, JP001, paxalisib, Toca 511 (vocimagen amiretrorepvec), chlorogenic acid, lutetoxyoctreotide, infigratinib, heat shock protein-peptide complex-96 (vitespen), lenvatinib, pemigatinib, sintilimab, camrelizumab, selinexor, neratinib, olaparib, anlotinib, niraparib, pembrolizumab, sacituzumab, recombinant cytokine gene-derived protein, apatinib, abemaciclib, crenolanib, ONC201, Sym004, etirinotecan pegol), napabucasin, paclitaxeltrevatide), dichloroacetic acid, ivophosphamide, girentuximab, adoxirubicin, 11C-methionine, 2,2,6,6-tetramethylpiperidinoxide, asunercept, TGF-β / Smad inhibitor (galunisertib), NVX-108, 18F-FET, 18F-fluoromisonidazole, ACT001, ALECSAT, CC-115, CX-02, GC1118, GSC-DCV, IGV-001, INXN-2001, LB-100, MDNA55, QBS10072S, RX108, SGT-53, SurVaxM, TLX101-CDx, TRC102, VXM01, abeo taxane, anti-EGFRvIII CAR T cells, audencel, berubicin, lerapolturev, lisavanbulin, olinvacimab, poly-ICLC, pp65-flLAMP DC, pp65-shLAMP DC, ragifilimab, DNX-2401 (tasadenoturev), varisacumab, varlilumab, veledimex, efineptakin α, pritumumab, 2X-111, BPM 31510, GWP42003 IV, OKN-007, SONALA-001, cabozantinib, pamiparib, iniparib, epacadostat, BMX-001, TAS0313, bemcentinib, NOX-A12 (olaptesed pegol), perillyl alcohol, B7-H3 CAR-T, CC-90010, D2C7-IT, EGFRBi-aATC, EO2401, EphA2-CAR-T, FG001, GLR2007, IMA950, INO-5401, M032, MM-D37K, NGM707, NMS-P293, PNK-007, ParvOryx, rhenium nanoliposomesnanoLiposomes), SL-701, ST101, TG6002, TLX101, Temferon, VBI-1901, olutasidenib, zotiraciclib, rosopatamab, ibrutinib, cemiplimab, zimberelimab, ketoconazole, AB154 (domvanalimab), BMS-986205 (linrodostat), AN1004 (pelareorep), MBG453 (sabatolimab), BI 907828, C225-ILs-dox, DEP-docetaxel, PU-HZ151 (Icapamespib), CUDC-907 (fimepinostat), LY3214996 (temuterkib), EDO-S101 (tinostamustine), adecatumumab, AU101, KB004 (ifabotuzumab), MTX110, nimotuzumab, 68Ga-BBN-IRDye800CW, 68GaFF-10158, 8R-70CAR T cells, AMAX-126, AZD1390, Ad-hCMV-Flt3L, Ad-hCMV-TK, B7-H3-targeted CAR-T cells, BDTX-1535, C134, C5252, CART-EGFR-IL13Ra2, CB-NK-TGF-betaR2- / NR3C1, CD147-CAR T, CD200AR-L, CHM-1101, CM93, DNX-2440, EGFR(V)-EDV-Dox, EGFRvIII-CAR T cells, ERAS-801, EphA2-redirected CAR T cells, GNOS-PV01, HER2.taNK, ICT-121, INB-200, ITM-31, JL15003, KD-025, KROS-201, KX02, LXF821, MB-101, MB-103, MT-201, NK celltherapy, NNV1, NP751, NU-0129, NeoVax, OS2966, PRT3645, PhOx430, Photobac, RMC-5552, RO7428731, TAS2940, WSD0922, XS15, XYF13, ZS / DC_P010, ZSP1602, autologousTris-CAR-T cells, chlorotoxin-directed CAR T cells, hEGFRvIII-CD3, serclutamab talirine, mibradil, tumor-infiltrating lymphocytes, WP1122, 68Ga-RMX-VH, KH617, EFE-G100, RZ001, ARX517, Alpha DaRT, JIN-001, Palomid529, YTX-7739, miltuximab, 177LuFF-10158, ALZ003, ATA274, AUM003, BA103, BDTX-700, BVAC-P, CAR-T EGFRvIII, CB-IC-01, CD20 CAR-NK, CK156, CNTY-103, CR13626, CUBT906, CYT-101, D-B483, EGFRvIII synNotch-CAR T cells, EO2315, EPC-002, Ena15, Ena21, F114, FG002, GBM-N019, GCK-03, GCT02, GLIX 1. GRm13Z40-2, GTA103, Gboxin, HBW-010, HM21001, HY-0201, HY-0301, IDP-410, IM 91. INB-300, INB-400, IST-205, ITI-1001, IVS-5001, JCN037, JCN068, JIN-002, K J-C2112, KSL-128114, LCC-09, LIN-2008, LM-001, LP-184, LQ103, MPT0B291, NKG2D CAR-T, NPT520-337, NSC139021, NSC765689, OCX-909, ONCR-719, PAS-403, PAT-DX1, PAT-DX1-NP, PC-0 02p, PPRX-1701, PT586, PT698, RAD102, RAD601, RAD602, RGLS5579, RapaBlock, SENL201, SGN2, SRI-21 979, SRI-30052, SRI-37683, SRI-37684, SVX-GB, SynKIR-410, TARG10, TARG9, TB101, THG-009, TTX-MC 138. TXB4-BC2, TXB4-BC3, VER-239353, VG204, VT-01, VT-Tri(2)-G, X4P-002, XH30, [18F]FE-OTS964.

[0049] In a preferred embodiment, in the use of the therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, the at least one additional active agent is a non-therapeutic agent.

[0050] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting the IGF1R gene or a composition thereof disclosed herein, the non-therapeutic agent is selected from: antiemetics, antianemic drugs, antimucositis drugs, hypoglycemic drugs, hypolipidemic drugs, and antihypertensive drugs.

[0051] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, the non-therapeutic agent is selected from: ondansetron, granisetron, dolasetron, palonosetron, metformin, simvastatin, and lacidipine.

[0052] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting the IGF1R gene or a composition thereof disclosed herein, the glioma is selected from the group consisting of adult-type diffuse glioma, childhood-type diffuse low-grade glioma, childhood-type diffuse high-grade glioma, localized astrocytic glioma, and combinations thereof, based on histological characteristics and molecular phenotype classification.

[0053] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting the IGF1R gene or a composition thereof disclosed herein, the adult diffuse glioma is selected from: IDH mutant astrocytoma, IDH mutant oligodendroglioma with 1p / 19q combined deletion, IDH wild-type glioblastoma, and a combination thereof.

[0054] The childhood diffuse low-grade glioma is selected from the group consisting of: MYB or MYBL1 variant diffuse astrocytoma, angiocentric glioma, juvenile multiforme low-grade neuroepithelial tumor, MAPK signaling pathway variant diffuse low-grade glioma, and combinations thereof.

[0055] The pediatric diffuse high-grade glioma is selected from the group consisting of: H3 K27 mutant diffuse midline glioma, H3 G34 mutant diffuse cerebral hemispheric glioma, H3 wild-type diffuse pediatric high-grade glioma, IDH wild-type diffuse pediatric high-grade glioma, infantile hemispheric glioma, and combinations thereof.

[0056] The localized astrocytic glioma is selected from the group consisting of: pilocytic astrocytoma, high-grade astrocytoma with pilocytic features, pleomorphic xanthoastrocytoma, and combinations thereof.

[0057] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting the IGF1R gene or a composition thereof disclosed herein, according to pathological classification, the glioma is selected from the group consisting of diffuse glioma, diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, oligoastrocytoma, childhood diffuse glioma, medulloblastoma, other embryonic tumors, anaplastic pleomorphic xanthoastrocytoma, multilayered rosette-like embryonic tumor, ependymoma and a combination thereof.

[0058] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting the IGF1R gene or a composition thereof disclosed herein, the cells involved in the glioma are selected from one or more of the following according to pathological cytological classification: human glioma cell line U87, human glioma cell line U251, and human glioma cell line SHG-44.

[0059] In a preferred embodiment, in the use of the therapeutically effective amount of the phosphorothioate antisense oligonucleotide targeting IGF1R gene or the composition thereof disclosed herein, the phosphorothioate antisense oligonucleotide targeting IGF1R gene or the composition thereof is formulated as a lyophilized agent or an injection.

[0060] In a preferred embodiment, in the use of a therapeutically effective amount of a thiocyanate antisense oligonucleotide targeting the IGF1R gene or a composition thereof disclosed herein, the thiocyanate antisense oligonucleotide targeting the IGF1R gene or a composition thereof is used in combination with one or more anti-cancer treatments, one or more cytostatic, cytotoxic or anticancer agents, targeted therapy or a combination of any of the foregoing.

[0061] In a preferred embodiment, in the use of a therapeutically effective amount of a phosphorothioate antisense oligonucleotide targeting IGF1R gene or a composition thereof disclosed herein, the anticancer therapy is selected from: surgical resection, chemotherapy, radiotherapy, biological therapy, bone marrow transplantation, and stem cell transplantation.

[0062] The phosphorothioate antisense oligonucleotide targeting the IGF1R gene or its composition or therapeutic combination disclosed herein is administered at an appropriate dose depending on different circumstances, including the pharmacokinetics, pharmacodynamics, administration mode, administration route, age, mental state, gastrointestinal function state of the recipient, severity of the disease and treatment duration.

[0063] The beneficial effects achieved by the present disclosure are at least as follows:

[0064] The present invention discloses a fully sulfhydryl antisense oligonucleotide S-ASODN-1 designed and synthesized with the mRNA sequence of insulin-like growth factor-1 receptor IGF1R as the target, which has a good effect in treating human glioma.

[0065] 1. The fully sulfur-substituted antisense oligonucleotide S-ASODN-1 has a good effect in inhibiting the proliferation of human glioma cells.

[0066] For example, S-ASODN-1 exhibited significant cell proliferation inhibitory effects on human glioma cell lines U87, U251, and SHG-44.

[0067] 1-1. Within 24 to 72 hours of action, S-ASODN-1 had a significant inhibitory effect on a variety of human glioma cells, while S-ASODN-2 to -5 had no inhibitory effect.

[0068] Experimental results showed that not all antisense oligonucleotides targeting IGF1R are effective in treating gliomas. This series of fully phosphorothioated antisense oligonucleotides showed significant differences in their inhibitory activity against glioma cells. Among them, S-ASODN-1 exhibited a significant proliferation inhibitory effect, significantly outperforming the positive control, cisplatin. In contrast, the other antisense oligonucleotide sequences, S-ASODN-2, S-ASODN-3, S-ASODN-4, and S-ASODN-5, failed to inhibit glioma cell proliferation or tumor growth and therefore cannot be used to treat gliomas.

[0069] 1-2. Within 24h to 72h of treatment, S-ASODN-1 has a significant inhibitory effect on the proliferation of various human glioma cells. Taking U87, U251, and SHG-44 cells as an example, the inhibitory effect on U87 is the best.

[0070] Specifically, when the dosage concentration of S-ASODN-1 was 1600nM, the inhibition rates of U87, U251 and SHG-44 cells after 24 hours of action were 65.58%, 62.96% and 61.16% respectively; the inhibition rates after 48 hours of action were 65.83%, 65.31% and 62.86% respectively; and the inhibition rates after 72 hours of action were 67.82%, 66.82% and 63.67% respectively.

[0071] 1-3. S-ASODN-1 inhibits the proliferation of glioma cells in a dose-dependent manner.

[0072] The inhibitory effect of S-ASODN-1 on the proliferation of various glioma cells (eg, U87, U251, SHG-44 cell lines) is dose-dependent, and the inhibitory effect gradually increases with the increase in the concentration of S-ASODN-1.

[0073] 1-4. S-ASODN-1 has a sustained inhibitory effect on the proliferation of glioma cells.

[0074] S-ASODN-1 has a sustained inhibitory effect on the proliferation of various human glioma cell lines (e.g., U87, U251, and SHG-44 cell lines). The inhibitory activity of S-ASODN-1 on cell proliferation gradually increases over one to three days.

[0075] 2. The fully sulfur-substituted antisense oligonucleotide S-ASODN-1 has a good effect in inhibiting the growth of glioma in mice.

[0076] 2-1. S-ASODN-1 has a significant inhibitory effect on the growth of glioma subcutaneously bearing nude mice.

[0077] Among them, the results of the growth inhibition experiment of human glioma cell line U87, U251, and SHG-44 transplant tumor models showed that each S-ASODN-1 administration group had an inhibitory effect on the growth of human glioma cell tumors. Although the inhibitory effect of the low-dose group (3.75 mg / kg) was slightly lower than that of the positive control sorafenib group (20 mg / kg), the inhibitory effects of the medium-dose group (7.5 mg / kg) and the high-dose group (15 mg / kg) were significantly better than those of the positive control sorafenib. Different dose groups can effectively inhibit the growth of glioma tumors and are used to treat gliomas. BRIEF DESCRIPTION OF THE DRAWINGS

[0078] Figure 1 This is a graph showing the inhibitory effect of S-ASODN-1 at different concentrations and treatment times on the proliferation of human glioma cell line U87;

[0079] Figure 2 This is a graph showing the inhibitory effect of S-ASODN-1 at different concentrations and treatment times on the proliferation of human glioma cell line U251;

[0080] Figure 3 This is a graph showing the inhibitory effect of S-ASODN-1 at different concentrations and treatment times on the proliferation of human glioma cell line SHG-44;

[0081] Figure 4 The effect of S-ASODN-1 on the tumor weight of mice bearing the human glioma cell line U87;

[0082] Figure 5 The effect of S-ASODN-1 on the tumor weight of mice bearing the human glioma cell line U251;

[0083] Figure 6 The effect of S-ASODN-1 on the tumor weight of mice bearing the human glioma cell line SHG-44. DETAILED DESCRIPTION

[0084] Example

[0085] Example 1: Synthesis of fully phosphorothioated antisense oligonucleotides

[0086] 1. Synthesis of fully phosphorothioated antisense oligonucleotide S-ASODN-1

[0087] S-ASODN-1 (sequence: 5'-TCCTCCGGAGCCAGACTTCA-3' (SEQ ID NO: 1)) was synthesized by solid-phase synthesis using a GE OligoPilot 400 synthesizer. The synthesis steps are as follows:

[0088] 1) Deprotection

[0089] A toluene solution of dichloroacetic acid is used as a deprotection reagent to remove the 5'-DMT protecting group of the starting nucleoside dA(bz) on the carrier, thereby releasing the 5'-hydroxyl group.

[0090] 2) Coupling

[0091] Acetonitrile is used as solvent and 5-ethylthiotetrazolyl is used as an activator to activate the dC(bz) phosphoramidite monomer to form an active intermediate, which then undergoes a condensation reaction with the 5'-hydroxyl group of the nucleoside dA(bz) for coupling.

[0092] 3) Thio

[0093] Using hydrogenated xanthan gum as a thio reagent, phosphites are oxidized into stable thiophosphates.

[0094] 4) Hydroxyl protection

[0095] Acetic anhydride is used as a protecting agent to protect the 5'-hydroxyl group of the nucleoside that has not undergone coupling reaction.

[0096] Repeat the above steps 1)-4) until the S-ASODN sequence coupling is completed.

[0097] 5) Deprotection

[0098] Using dichloroacetic acid as a deprotection reagent, the DMT protecting group of the last nucleoside dT is removed to obtain S-ASODN-1 connected to a carrier.

[0099] 6) Ammonolysis

[0100] Add concentrated ammonia to perform an aminolysis reaction, hydrolyzing the ester bond between the carrier and the nucleotide and removing the protecting groups on phosphate, adenine, guanine, and cytosine. Filter, rinse with ethanol and water, and collect the filtrate.

[0101] 7) Purification

[0102] The filtrate was purified by reverse phase column chromatography and freeze-dried to obtain the product with a purity of 93.9%.

[0103] 2. Synthesis of fully phosphorothioated antisense oligonucleotides S-ASODN-2-5

[0104] The synthesis methods of the fully phosphorothioated antisense oligonucleotides S-ASODN-2 (sequence: 5'-TTCATTCCTTTTATTTGGGA-3' (SEQ ID NO: 2)), S-ASODN-3 (sequence: 5'-GGACCCTCCTCCGGAGCC-3' (SEQ ID NO: 3)), S-ASODN-4 (sequence: 5'-GAGAAACAGGAGCCCCCACA-3' (SEQ ID NO: 4)), and S-ASODN-5 (sequence: 5'-GCGCGGCTGGAAAGCGCGTT-3' (SEQ ID NO: 5)) were the same as above, and the purities were 92.6%, 93.4%, 94.2%, and 94.6%, respectively.

[0105] Example 2: Cell proliferation inhibition experiment

[0106] 1. Experimental Materials

[0107] Test samples: the fully phosphorothioated antisense oligonucleotides S-ASODN-1, S-ASODN-2, S-ASODN-3, S-ASODN-4 and S-ASODN-5 synthesized in Example 1.

[0108] Cell types: human glioma cell line U87 (Guangzhou Saiku Biotechnology Co., Ltd.), human glioma cell line U251 (Guangzhou Saiku Biotechnology Co., Ltd.), human glioma cell line SHG-44 (Guangzhou Saiku Biotechnology Co., Ltd.).

[0109] Positive control drug: Cisplatin

[0110] Drug solvent: sodium chloride injection

[0111] 2. Experimental Methods

[0112] The WST-1 Cell Proliferation and Cytotoxicity Assay Kit (purchased from Shanghai Beyotime Biotechnology Co., Ltd., product number C0036) (MTT-like method) was used to detect the growth inhibition of the test samples on human glioma cell lines U87, U251, and SHG-44, with cisplatin as a positive control.

[0113] The WST-1 cell proliferation and cytotoxicity detection kit includes WST-1 (powder)*1 bottle and electron coupling reagent*5mL.

[0114] Preparation of WST-1 solution: Add 5 ml of electron coupling reagent to WST-1 powder and dissolve it completely to form WST-1 solution.

[0115] In the experiment, 2000 cells were added to each well in 100 μl and cultured. Different concentrations of perphosphorylated antisense oligonucleotides were then stimulated. 10 μl of WST-1 solution was added to each well. A blank control was performed using wells containing the same amount of cell culture medium and WST-1 solution but no cells. Incubate in a cell culture incubator for 1-2 hours. The 96-well plate was shaken on a shaker for 1 minute to thoroughly mix the assay. The absorbance was measured at 450 nm.

[0116] 2.1 Cell culture

[0117] Subcultured U87, U251, and SHG-44 cell lines were cultured in logarithmically growing cells in DMEM-F12 medium (supplemented with 100 μL / mL each of penicillin and streptomycin) with 10% fetal bovine serum at 37°C in a cell culture incubator with 5% CO2, with the medium changed daily. The cells were then digested and subcultured using 0.25% trypsin. After centrifugation at 1000 rpm for 5 minutes, the supernatant was discarded and fresh medium was added for subculture.

[0118] 2.2 Cell transfection

[0119] Seed the cells into a 96-well plate in advance, with 5000 cells per well, and replace the culture medium with new one before the experiment while ensuring that the cells are attached. Add 0.3μL Lipo3000 transfection reagent to 5μL Opti-MEM medium, shake to mix, and centrifuge briefly. Add the corresponding concentrations of the sample to be transfected (final concentrations are: 0nM, 100nM, 200nM, 400nM, 800nM, 1600nM) and 0.4μL P3000 reagent to 5μL Opti-MEM medium, shake to mix, and centrifuge briefly. Add the diluted sample to be transfected to each tube of diluted Lipo3000 reagent. Each mixing tube contains the reagent components. Incubate at room temperature for 15 minutes, and add the incubated transfection reagent to the prepared cells.

[0120] In addition, a blank control group (no reagent was added, only cells) and a positive control group (cisplatin administration concentration was 5 μM) were set up.

[0121] 2.3 Cell proliferation assay

[0122] Use the WST-1 cell proliferation and cytotoxicity assay kit. Add 10 μL of WST-1 solution to 100 μL of culture medium. Incubate in a cell culture incubator for another hour. Place the cell culture plate on a shaker for one minute to mix thoroughly. Measure the absorbance (OD) at 450 nm.

[0123] 2.4 Data Processing

[0124] Calculate the cell survival rate (%) and proliferation inhibition rate (%) using the following formula:

[0125] Survival rate (%) = (OD value of experimental group / OD value of blank control group) × 100%;

[0126] Inhibition rate (%) = 1 - survival rate (%).

[0127] 3. Experimental Results

[0128] 3.1 When the action time was 72h, S-ASODN-1 had a significant inhibitory effect on various human glioma cells, while S-ASODN-2 to 5 had no inhibitory effect

[0129] The experimental results showed that when the action time was 72h, S-ASODN-1 had the best inhibitory effect on the proliferation of human glioma U87, U251, and SHG-44 cells, showing inhibitory activity at 100nM. S-ASODN-2~5 had no inhibitory effect on the growth of human glioma cells within the concentration range of 0~1600nM.

[0130] The specific experimental results are as follows:

[0131] Table 4 Inhibitory effect of antisense oligonucleotide S-ASODN series on human glioma cell proliferation

[0132]

[0133] As shown in Table 4, the synthetic all-phosphorothioate antisense oligonucleotide sequences S-ASODN-2-5 had no inhibitory effect on the growth of human glioma U87, U251, and SHG-44 cells within a concentration range of 0 to 1600 nM. S-ASODN-1 exhibited the strongest inhibitory effect on cell proliferation, exhibiting inhibitory activity at 100 nM, with the inhibitory effect increasing with increasing concentration. Furthermore, after a 72-hour exposure, the inhibitory rates of S-ASODN-1 on U87, U251, and SHG-44 cells at different dose concentrations were as follows:

[0134] When the drug concentration was 100 nM, the inhibition rates after 72 h were 59.21%, 56.11%, and 50.70%, respectively. The inhibition effects on different cell lines were all greater than 50%.

[0135] When the drug concentration was 200-800 nM, the inhibition rate was controlled at 52.00%-61.94% with an action time of 72 h.

[0136] When the drug concentration was 1600nM, the inhibition rates after 72h were 67.82%, 66.82% and 63.67% respectively. The inhibition effects on different cell lines were all greater than 60%, with the highest reaching over 67%.

[0137] This indicates that antisense oligonucleotide sequences targeting the mRNA sequence of the insulin-like growth factor-1 receptor (IGF1R) have significantly different inhibitory effects on glioma cells from different cell lines. Not all antisense oligonucleotides targeting IGF1R are capable of treating gliomas. For example, S-ASODN-1, an antisense oligonucleotide with a specific sequence targeting the insulin-like growth factor-1 receptor (IGF1R), can effectively inhibit glioma cell proliferation and is used to treat gliomas. In contrast, other antisense oligonucleotide sequences disclosed herein, S-ASODN-2, S-ASODN-3, S-ASODN-4, and S-ASODN-5, are unable to inhibit glioma cell proliferation and cannot be used to treat gliomas.

[0138] 3.2 Within 24h to 72h of treatment, S-ASODN-1 had a significant inhibitory effect on the proliferation of various human glioma cells, among which the inhibitory effect on U87 was the best.

[0139] The above experiment investigated the inhibitory effect of the antisense oligonucleotide sequence S-ASODN-1 to 5 series on the proliferation of human glioma U87, U251, and SHG-44 cells. It was found that only S-ASODN-1 had a significant inhibitory effect on the above human glioma cell lines, while the other S-ASODN-2 to 5 had no inhibitory effect.

[0140] The following content further explores the inhibitory effect of S-ASODN-1 on human glioma cell proliferation at different action times.

[0141] The results showed that S-ASODN-1 had an inhibitory effect on the proliferation of human glioma cell lines U87, U251, and SHG-44 within 24h to 72h, and had the best inhibitory effect on the U87 cell line.

[0142] The specific experimental results are as follows:

[0143] Table 5 Inhibitory effect of antisense oligonucleotide S-ASODN-1 on human glioma cell proliferation

[0144]

[0145] As can be seen from Table 5, S-ASODN-1 has an inhibitory effect on the proliferation of human glioma cell lines U87, U251, and SHG-44.

[0146] 1) Inhibitory effect on U87 cell line

[0147] S-ASODN-1 inhibited the proliferation of the U87 cell line at a concentration of 100 nM. Over time, the inhibition rate ranged from 48.43% to 67.82% at concentrations between 100 nM and 1600 nM, showing a steadily increasing inhibitory effect. At concentrations between 100 nM and 1600 nM, the inhibition rate exceeded that of the positive control by 8% to 23%. At a concentration of 1600 nM and an exposure time of 24 hours, the inhibition rate exceeded the positive control by 25.97%, significantly exceeding the positive control.

[0148] 2) Inhibitory effect on U251 cell line

[0149] S-ASODN-1 effectively inhibited the proliferation of U251 cells at concentrations ranging from 100 nM to 1600 nM. The 24-hour inhibition rate ranged from 49.98% to 62.96%, exceeding the positive control (41.54%) by 8.44% to 21.42%. The 48-hour inhibition rate ranged from 50.44% to 65.31%, exceeding the positive control (43.04%) by 7.40% to 22.27%. The 72-hour inhibition rate ranged from 56.11% to 66.82%, exceeding the positive control (45.12%) by 10.99% to 21.70%. The efficacy of S-ASODN-1 at concentrations ranging from 100 nM to 1600 nM was higher than that of the positive control over varying time periods, with the inhibition rate exceeding 65% at a concentration of 1600 nM.

[0150] 3) Inhibitory effect on SHG44 cell line

[0151] S-ASODN-1 can inhibit the proliferation of SHG44 cells at a concentration of 100 nM. At concentrations ranging from 100 nM to 1600 nM, the inhibition rate was superior to that of the positive control cisplatin at 24 to 72 hours with prolonged exposure. At different dosage concentrations of 100nM, 200nM, 400nM, 800nM and 1600nM, under 24h conditions, the inhibition rates were 43.59%, 50.33%, 52.14%, 58.42% and 61.16%, respectively, exceeding the inhibition rate of the positive control cisplatin (38.74%) by 4.85% to 22.42%; under 48h conditions, the inhibition rates were 47.81%, 52.36%, 54.40%, 58.87% and 62.86%, respectively, exceeding the inhibition rate of the positive control cisplatin (43.34%) by 4.47% to 19.52%; under 72h conditions, the inhibition rates were 50.70%, 52.00%, 55.39%, 58.99% and 63.67%, respectively, exceeding the inhibition rate of the positive control cisplatin (44.11%) by 6.59% to 19.56%.

[0152] The experimental results showed that the inhibitory activity of this series of fully phosphorylated antisense oligonucleotides on lung cancer cells varied greatly. The antisense oligonucleotide sequence S-ASODN-1 targeting the mRNA sequence of the insulin-like growth factor-1 receptor IGF1R had a significant inhibitory effect on the proliferation of human glioma cell lines U87, U251, and SHG-44.

[0153] As shown in Table 5, through statistical analysis, S-ASODN-1 exhibited significant growth inhibitory effects on three cell lines, namely U87, U251, and SHG-44, on the first day.

[0154] Among them, S-ASODN-1 showed the highest inhibitory effect on the human glioma cell line U87. At a concentration of 1600 nM, the inhibitory rates of S-ASODN-1 on U87, U251, and SHG44 cells were 65.58%, 62.96%, and 61.16% after 24 hours of exposure; 65.83%, 65.31%, and 62.86% after 48 hours of exposure; and 67.82%, 66.82%, and 63.67% after 72 hours of exposure.

[0155] Compared with the control cisplatin inhibition rate, the order of improvement in the proliferation inhibition effect of S-ASODN-1 on each cell line (from large to small compared with the control cisplatin inhibition rate) is: U87>U251>SHG44, and the inhibition rate effect is significant.

[0156] 3.3S-ASODN-1 has a significant inhibitory effect on the proliferation of various human glioma cell lines

[0157] Based on the results of the above Table 5 on the inhibitory effect of S-ASODN-1 on human glioma cell proliferation at different times and concentrations, a significance analysis of the survival rate of the cell proliferation inhibition test was performed.

[0158] The survival rates of different concentrations (100nM, 200nM, 400nM, 800nM, 1600nM) were compared with those of the negative group (0nM) and the blank control group (Mock group containing only the same cells without adding reagents) for significance analysis.

[0159] The proliferation inhibition test of each tumor cell line was repeated 3 times, and the survival rate was calculated. See the table below.

[0160] Statistical analysis between groups was performed using the t-test program in Excel software. Significant differences were analyzed between transfected samples at different concentrations relative to the blank control group and between transfected samples at different concentrations relative to the negative control group. For p < 0.05, * indicates a slight difference; for p < 0.01, ** indicates a significant difference; and for p < 0.001, *** indicates a highly significant difference.

[0161]

[0162]

[0163] As can be seen from the above table, for human glioma cells of different cell lines, as the dosage concentration increases from 100nM to 1600nM and the action time prolongs from 24h to 72h, the p-value obtained from the test is much less than 0.05, indicating that the survival rate of the experimental group is different from that of the blank group or the negative group; and, the p-value of the overall data in the above table is <0.001, indicating that the survival rate of the experimental group is highly significantly different from that of the blank group or the negative group, that is, S-ASODN-1 significantly improves and enhances the survival rates of human glioma U87, U251, and SHG-44 cell lines.

[0164] 3.4S-ASODN-1 inhibits the proliferation of glioma cell lines in a dose-dependent manner

[0165] From the above experimental results, it can be seen that S-ASODN-1 has a significant inhibitory effect on the proliferation of various glioma cell lines.

[0166] We further explored the relationship between the inhibitory effect of S-ASODN-1 on the proliferation of various glioma cell lines and the dose of S-ASODN-1, and proved that its inhibitory effect was dose-dependent.

[0167] The results on the first day after cell transfection showed that as the concentration of S-ASODN-1 increased (100 nM to 1600 nM), the proliferation inhibitory effect on human glioma cell lines was significantly enhanced.

[0168] Specifically: when the action time is 72h, the drug concentration is gradually increased, that is, the drug concentration is 100nM, 200nM, 400nM, 800nM and 1600nM respectively.

[0169] The inhibition rates of S-ASODN-1 on U87 cells were 59.21%, 59.78%, 59.79%, 61.94% and 67.82% respectively;

[0170] The inhibition rates of S-ASODN-1 on U251 cells were 56.11%, 58.44%, 59.55%, 59.10% and 66.82% respectively;

[0171] The inhibition rates of S-ASODN-1 on SHG44 cells were 50.70%, 52.00%, 55.39%, 58.99% and 63.67% respectively.

[0172] From the above data, it can be seen that the proliferation inhibition rate of S-ASODN-1 on different human glioma cell lines increases with the increase of administration concentration, indicating that the proliferation inhibition of S-ASODN-1 on human glioma cell lines is dose-dependent.

[0173] 3.5S-ASODN-1 has a sustained inhibitory effect on the proliferation of human glioma cell lines

[0174] In addition to the above-mentioned investigation into the dose-dependence of the effects of S-ASODN-1, the duration of the proliferation inhibitory effect of S-ASODN-1 was also investigated in a variety of human glioma cell lines. The results showed that the proliferation inhibitory effect of S-ASODN-1 on a variety of human glioma cell lines was sustained.

[0175] Duration of action is not only a key indicator for evaluating antisense nucleic acid drugs, but also provides valuable insights into dosing regimens. The experimental results above demonstrate that S-ASODN-1's inhibitory activity against glioma cells gradually increases over days 1 to 3. By day 3, S-ASODN-1's inhibitory rate on glioma cell proliferation reached a peak of over 60% to 65%, demonstrating a significant inhibitory effect on glioma cell proliferation.

[0176] Specifically, when the administration concentration of S-ASODN-1 was 1600nM, as the administration time prolonged, the inhibition rates on U87 cells were 65.58%, 65.83% and 67.82% at administration times of 24h, 48h and 72h, respectively; the inhibition rates on U251 cells were 62.96%, 65.31% and 66.82%, respectively; the inhibition rates on SHG44 cells were 61.16%, 62.86% and 63.67%, respectively. As the administration time prolonged, it exerted a significant inhibitory effect on human glioma U87 cells, U251 cells and SHG44 cells.

[0177] Based on the experimental results in the above examples, S-ASODN-1 demonstrated significant proliferation inhibition against human glioma cells (U87, U251, and SHG-44), with this effect being dose-dependent and persistent. S-ASODN-1 exhibited the highest inhibitory effect against the human glioma cell line (U87). Furthermore, experiments were conducted to investigate the growth inhibition of S-ASODN-1 in a subcutaneous nude mouse model of human glioma.

[0178] Example 3: Growth inhibition experiment of S-ASODN-1 on human glioma subcutaneous nude mouse tumor model

[0179] 1. Experimental Materials

[0180] Test sample: the fully phosphorothioate antisense oligonucleotide S-ASODN-1 synthesized in Example 1

[0181] (Sequence: 5'-TCCTCCGGAGCCAGACTTCA-3')

[0182] Cell types: Human glioma cell lines U87, U251, SHG44

[0183] Positive drug: Sorafenib

[0184] Drug solvent: sodium chloride injection

[0185] Experimental animals: 4-6 weeks old Nu / Nu nude mice, weighing 20.0±2g, 100 males and females, purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd. The test animals were housed in sterile, independently ventilated IVC cages, with 5-6 mice per cage. The bedding was 60 Co-irradiated corn cob bedding, particle size 4-6 mm. Mice were fed a sterilized diet specifically formulated for mice and had free access to purified water. The animal laboratory was maintained at approximately 25°C, relative humidity 40-70%, and daylight hours 12 hours per day.

[0186] 2. Experimental Methods

[0187] 2.1 Cell culture

[0188] U251, U87, and SHG44 cells were cultured in DMEM-F12 medium supplemented with 10% fetal bovine serum (100 μL / mL each of penicillin and streptomycin) in a 37°C incubator with 5% CO2. The medium was changed daily. Cells were digested and passaged using 0.25% trypsin. After centrifugation at 1000 rpm for 5 minutes, the supernatant was discarded and fresh medium was added for subculture.

[0189] 2.2 Preservation of subcutaneous transplant tumor model

[0190] The subcultured human glioma cells U251, U87, and SHG44 were digested into suspensions under sterile conditions, rinsed with sodium chloride injection, and resuspended into suspensions, which were then subcutaneously inoculated into the axilla of the right forelimb of nude mice for seed preservation.

[0191] 2.3 Experimental groups and treatment plans:

[0192] One week after tumor cell inoculation, when tumor tissue protrusions were observable with the naked eye, animals with similar tumor sizes were randomly divided into five groups according to their weight, namely, the blank model control group (blank control group), the low-dose S-ASODN-1 (3.75 mg / kg) group, the medium-dose S-ASODN-1 (7.5 mg / kg) group, the high-dose S-ASODN-1 (15 mg / kg) group, and the positive control sorafenib (20 mg / kg) group.

[0193] Specific dosing and treatment methods for each group:

[0194] Blank model control group: A mouse glioma model was constructed according to the above method. After the model was successfully established, purified water was administered orally once every 24 hours for a total of 20 days. The body weight of the mice was measured at the beginning and after the completion of the experiment.

[0195] S-ASODN-1 low-, medium-, and high-dose groups: A mouse glioma model was constructed according to the above method. After successful modeling, each group of mice was injected into the tail vein with a given dose, which was 3.75 mg / kg for the low-dose group, 7.5 mg / kg for the medium-dose group, and 15 mg / kg for the high-dose group. The doses were administered once every 48 hours for 10 consecutive times for a total of 20 days. The mice were weighed at the beginning and after the completion of the experiment.

[0196] Positive control group: A mouse glioma model was constructed according to the above method. After the model was successfully established, sorafenib was administered by gavage once every 24 hours for a total of 20 days. The mice were weighed at the beginning and after the completion of the experiment.

[0197] After the experiment, the animals were killed by cervical dislocation. The tumor tissue was removed by dissection, and the visible tumor was peeled off and weighed.

[0198] 2.4 Data Processing

[0199] Orthotopic transplant tumor weight data are expressed as X ± S (mean ± standard deviation);

[0200] Tumor net weight inhibition rate = (tumor net weight of blank model control group - tumor net weight of drug-treated group) / tumor net weight of blank model control group × 100%.

[0201] 3. Experimental Results

[0202] Tumor weight directly reflects the size of glioma tumors. The curve trends of different groups show that the medium-dose group (7.5 mg / kg) of S-ASODN-1 has the same glioma inhibition effect as the positive drug sorafenib group, and the glioma inhibition rate of the S-ASODN-1 test drug is dose-dependent.

[0203]

[0204] As shown in the table above, during the administration period, animals in all groups except the blank model control group died.

[0205] In the low-dose group, 0 animals in the U87 cell line died, 2 animals in the U251 cell line died, and 2 animals in the SHG44 cell line died.

[0206] In the medium-dose group, 1 animal in the U87 cell line died, 0 animals in the U251 cell line died, and 2 animals in the SHG44 cell line died.

[0207] In the high-dose group, one animal in the U87 cell line died, one animal in the U251 cell line died, and one animal in the SHG44 cell line died.

[0208] In the positive control group, 2 animals of U87 cell line died, 0 animals of U251 cell line died, and 3 animals of SHG44 cell line died when the animals were administrated.

[0209] For the U87 cell line, the tumor weights in each group were: 99.02±47.89 mg in the blank model control group, 72.42±12.83 mg in the positive control sorafenib group, 82.82±14.45 mg in the low-dose S-ASODN-1 group, 63.27±8.83 mg in the medium-dose group, and 41.938±15.95 mg in the high-dose group. Compared with the blank model control group, all treatment groups significantly inhibited tumor growth. The high-dose group had the best tumor inhibition effect, followed by the medium-dose group. Both groups showed significantly better tumor inhibition than the positive control sorafenib.

[0210] For the U251 cell line, the tumor weights in each group were: 89.88±48.53 mg for the blank model control group, 74.43±14.16 mg for the positive control sorafenib group, 87.72±5.88 mg for the low-dose S-ASODN-1 group, 65.92±13.83 mg for the medium-dose group, and 47.66±12.23 mg for the high-dose group. Compared with the blank model control group, all treatment groups significantly inhibited tumor growth. The high-dose group had the best tumor inhibition effect, followed by the medium-dose group. Both groups showed significantly better tumor inhibition than the positive control sorafenib.

[0211] For the SHG44 cell line, tumor weights in each group were: 106.74±53.25 mg in the blank model control group, 76.54±11.88 mg in the positive control sorafenib group, 95.92±19.96 mg in the low-dose S-ASODN-1 group, 66.57±10.41 mg in the medium-dose group, and 49.33±15.00 mg in the high-dose group. Compared with the blank model control group, all treatment groups significantly inhibited tumor growth. The high-dose group had the best tumor inhibition effect, followed by the medium-dose group. Both groups exhibited superior tumor inhibition effects compared to the positive control sorafenib.

[0212] Compared with the blank model control group, the net tumor weight inhibition rates of the positive control sorafenib group in different experimental groups were U87: 26.86%, U251: 17.18%, SHG44: 28.30%; the net tumor weight inhibition rates of the low-dose group were U87: 16.36%, U251: 2.40%, SHG44: 10.14%; the net tumor weight inhibition rates of the medium-dose group were U87: 36.11%, U251: 26.65%, SHG44: 37.63%; the net tumor weight inhibition rates of the high-dose group were U87: 57.65%, U251: 46.97%, SHG44: 53.78%.

[0213] From the above data, it can be seen that each S-ASODN-1 administration group has a significant inhibitory effect on the growth of human glioma cells. The low-dose group is slightly lower than the positive control sorafenib group, but the inhibitory effect of the medium-dose group and the high-dose group is significantly better than the positive control sorafenib. Different dose groups can significantly inhibit the growth of glioma tumors and are used to treat gliomas.

Claims

1. Use of a therapeutically effective amount of a thiocyanate antisense oligonucleotide targeting IGF1R gene or a composition thereof in the preparation of a medicament for inhibiting glioma cell proliferation and / or treating glioma in a subject suffering from glioma, wherein the sequence of the thiocyanate antisense oligonucleotide targeting IGF1R gene is a nucleotide sequence having more than 80% nucleotide identity with the sequence shown in SEQ ID NO:1, preferably a nucleotide sequence having more than 85%, 90%, 95%, 96%, 97%, 98%, 99% nucleotide identity; more preferably, the sequence of the thiocyanate antisense oligonucleotide targeting ICFIR gene is as shown in SEQ ID NO:

1.

2. The use according to claim 1, wherein the phosphorothioate antisense oligonucleotide targeting the IGF1R gene further has other chemical modifications.

3. The use according to claim 2, wherein the other chemical modifications are selected from one or more of the following: locked nucleic acid modification, 2-methoxyethyl modification and 2-oxymethyl modification.

4. Use according to any one of the preceding claims, wherein the composition further comprises at least one additional active agent.

5. The use according to claim 4, wherein the at least one additional active agent is a therapeutic agent or a non-therapeutic agent, or a combination of a therapeutic agent and a non-therapeutic agent.

6. The use according to claim 5, wherein the at least one additional active agent is a therapeutic agent selected from one or more of the following: temozolomide, lomustine, bevacizumab, SI-053, Gliovac, Immuncell-LC, ipilimumab, dehydrodulcitol, tofacitinib, regorafenib, nivolumab, cediranib, ADCTA-SSI-G1, AV-GBM-1, DCVax-L, ICT-107, ITK-1, ASC40 (denifanstat), marizomib, ofranergene obadenovec, personalized peptide vaccine, trabedersen, enzastaurin, crocetin, benzylguanine, OncoPLEX, flucytosine, vebreltinib, trigriluzole, veliparib, JP001, paxalisib, Toca 511 (vocimagene amiretrorepvec), chlorogenic acid, lutetoxyoctreotide, infigratinib, heat shock protein-peptide complex-96 (vitespen), lenvatinib, pemigatinib, sintilimab, camrelizumab, selinexor, neratinib, olaparib, anlotinib, niraparib, pembrolizumab, sacituzumab, recombinant cytokine gene-derived protein, apatinib, abemaciclib, crenolanib, ONC201, Sym004, etirinotecan pegol), napabucasin, paclitaxeltrevatide), dichloroacetic acid, ivophosphamide, girentuximab, adoxirubicin, 11C-methionine, 2,2,6,6-tetramethylpiperidinoxide, asunercept, TGF-β / Smad inhibitor (galunisertib), NVX-108, 18F-FET, 18F-fluoromisonidazole, ACT001, ALECSAT, CC-115, CX-02, GC1118, GSC-DCV, IGV-001, INXN-2001, LB-100, MDNA55, QBS10072S, RX108, SGT-53, SurVaxM, TLX101-CDx, TRC102, VXM01, abeo taxane, anti-EGFRvIIICAR T cells, audencel, berubicin, lerapolturev, lisavanbulin, olinvacimab, poly-ICLC, pp65-flLAMP DC, pp65-shLAMP DC, ragifilimab, DNX-2401 (tasadenoturev), varisacumab, varlilumab, veledimex, efineptakinα, pritumumab, 2X-111, BPM 31510, GWP42003 IV, OKN-007, SONALA-001, cabozantinib, pamiparib, iniparib, epacadostat, BMX-001, TAS0313, bemcentinib, NOX-A12 (olaptesed pegol), perillyl alcohol, B7-H3 CAR-T, CC-90010, D2C7-IT, EGFRBi-aATC, EO2401, EphA2-CAR-T, FG001, GLR2007, IMA950, INO-5401, M032, MM-D37K, NGM707, NMS-P293, PNK-007, ParvOryx, rhenium nanoliposomesnanoLiposomes), SL-701, ST101, TG6002, TLX101, Temferon, VBI-1901, olutasidenib, zotiraciclib, rosopatamab, ibrutinib, cemiplimab, zimberelimab, ketoconazole, AB154 (domvanalimab), BMS-986205 (linrodostat), AN1004 (pelareorep), MBG453 (sabatolimab), BI 907828, C225-ILs-dox, DEP-docetaxel, PU-HZ151 (Icapamespib), CUDC-907 (fimepinostat), LY3214996 (temuterkib), EDO-S101 (tinostamustine), adecatumumab, AU101, KB004 (ifabotuzumab), MTX110, nimotuzumab, 68Ga-BBN-IRDye800CW, 68GaFF-10158, 8R-70CAR T cells, AMAX-126, AZD1390, Ad-hCMV-Flt3L, Ad-hCMV-TK, B7-H3 targeted CAR-T cells, BDTX-1535, C134, C5252, CART-EGFR-IL13Ra2, CB-NK-TGF-betaR2- / NR3C1, CD147-CAR T, CD200AR-L, CHM-1101, CM93, DNX-2440, EGFR(V)-EDV-Dox, EGFRvIII-CAR T cells, ERAS-801, EphA2-redirected CAR T cells, GNOS-PV01, HER2.taNK, ICT-121, INB-200, ITM-31, JL15003, KD-025, KROS-201, KX02, LXF821, MB-101, MB-103, MT-201, NK celltherapy, NNV1, NP751, NU-0129, NeoVax, OS2966, PRT3645, PhOx430, Photobac, RMC-5552, RO7428731, TAS2940, WSD0922, XS15, XYF13, ZS / DC_P010, ZSP1602, autologousTris-CAR-T cells, chlorotoxin-directed CAR T cells, hEGFRvIII-CD3, serclutamab talirine, mirabidol, tumor-infiltrating lymphocytes, WP1122, 68Ga-RMX-VH, KH617, EFE-G100, RZ001, ARX517, Alpha DaRT, JIN-001, Palomid529, YTX-7739, miltuximab, 177LuFF-10158, ALZ003, ATA274, AUM003, BA103, BDTX-700, BVAC-P, CAR-T EGFRvIII, CB-IC-01, CD20 CAR-NK, CK156, CNTY-103, CR13626, CUBT906, CYT-101, D-B483, EGFRvIII synNotch-CAR T cells, EO2315, EPC-002, Ena15, Ena21, F114, FG002, GBM-N019, GCK-03, GCT02, GLIX 1. GRm13Z40-2, GTA103, Gboxin, HBW-010, HM21001, HY-0201, HY-0301, IDP-410, IM 91. INB-300, INB-400, IST-205, ITI-1001, IVS-5001, JCN037, JCN068, JIN-002, K J-C2112, KSL-128114, LCC-09, LIN-2008, LM-001, LP-184, LQ103, MPT0B291, NKG2D CAR-T, NPT520-337, NSC139021, NSC765689, OCX-909, ONCR-719, PAS-403, PAT-DX1, PAT-DX1-NP, PC-0 02p, PPRX-1701, PT586, PT698, RAD102, RAD601, RAD602, RGLS5579, RapaBlock, SENL201, SGN2, SRI-21 979, SRI-30052, SRI-37683, SRI-37684, SVX-GB, SynKIR-410, TARG10, TARG9, TB101, THG-009, TTX-MC 138. TXB4-BC2, TXB4-BC3, VER-239353, VG204, VT-01, VT-Tri(2)-G, X4P-002, XH30, [18F]FE-OTS964.

7. Use according to claim 5 or 6, wherein the at least one additional active agent is a non-therapeutic agent.

8. The use according to claim 7, wherein the non-therapeutic agent is selected from the group consisting of antiemetics, antianemic drugs, antimucositis drugs, hypoglycemic drugs, hypolipidemic drugs, and antihypertensive drugs.

9. The use according to claim 8, wherein the non-therapeutic agent is selected from the group consisting of ondansetron, granisetron, dolasetron, palonosetron, metformin, simvastatin, lacidipine.

10. The use according to any one of claims 1 to 9, in, According to histological characteristics and molecular phenotype classification, the glioma is selected from the group consisting of: adult diffuse glioma, childhood diffuse low-grade glioma, childhood diffuse high-grade glioma, localized astrocytic glioma and combinations thereof.

11. The use according to claim 10, in, The adult diffuse glioma is selected from: IDH mutant astrocytoma, IDH mutant with 1p / 19q combined deletion oligodendroglioma, IDH wild-type glioblastoma and a combination thereof.

12. The use according to claim 10, in, The pediatric diffuse low-grade glioma is selected from: MYB or MYBL1 variant diffuse astrocytoma, angiocentric glioma, juvenile multiforme low-grade neuroepithelial tumor, MAPK signaling pathway variant diffuse low-grade glioma and combinations thereof.

13. The use according to claim 10, in, The pediatric diffuse high-grade glioma is selected from: H3 K27 variant diffuse midline glioma, H3 G34 mutant diffuse cerebral hemispheric glioma, H3 wild-type diffuse pediatric high-grade glioma, IDH wild-type diffuse pediatric high-grade glioma, infantile hemispheric glioma and combinations thereof.

14. The use according to claim 10, in, The localized astrocytic glioma is selected from the group consisting of pilocytic astrocytoma, high-grade astrocytoma with pilocytic features, pleomorphic xanthoastrocytoma, and combinations thereof.

15. The use according to any one of claims 1 to 9, in, According to pathological cytological classification, the glioma is selected from: diffuse glioma, diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, oligoastrocytoma, childhood diffuse glioma, medulloblastoma, other embryonic tumors, anaplastic pleomorphic xanthoastrocytoma, multilayered rosette-like embryonic tumor, ependymoma and combinations thereof.

16. Use according to any one of the preceding claims, in, The cells involved in glioma cancer are selected from one or more of the following: human glioma cell line U87, human glioma cell line U251, and human glioma cell line SHG-44. 17 . The use according to any one of the preceding claims, wherein the phosphorothioate antisense oligonucleotide targeting IGF1R gene or the composition thereof is formulated as a lyophilized agent or an injection.

18. The use according to any one of the preceding claims, wherein the phosphorothioate antisense oligonucleotide targeting the IGF1R gene or a composition thereof is used in combination with one or more anti-cancer treatments, one or more cytostatic, cytotoxic or anti-cancer agents, targeted therapy or a combination of any of the foregoing.

19. Use according to any one of the preceding claims, wherein the anti-cancer therapy is selected from: surgical resection, chemotherapy, radiotherapy, biological therapy, bone marrow transplantation, stem cell transplantation.

Citation Information

Patent Citations

  • Application of antisense oligonucleotide in preparation of medicine for treating kidney cancer

    CN114306370A

  • Modified thio-oligonucleotides and uses thereof

    CN114369130A

  • Detection method of thio-oligonucleotide related substances

    CN114414712A

  • Antisense oligonucleotide structure and use of cell propagation receptor IGFIK

    CN1358859A